Skip directly to content

Improving Patient Care in Uncontrolled Acromegaly (IPCUA)

Pfizer is now inviting applications from UK Healthcare Organisations for Medical and Educational Goods and Services (MEGS) to support “Improving Patient Care in Uncontrolled Acromegaly”

 

When assessing whether a patient’s acromegaly is controlled or not, IGF-1 is an important measure to consider.  A serum IGF-I level is a good measure to assess integrated GH secretion and is excellent for diagnosis and monitoring. A random IGF-I value (a marker of integrated GH secretion) should be measured for diagnosis and for monitoring after a therapeutic intervention.1

 

We are particularly interested in receiving proposals that:

  • Review all acromegaly patients in order to identify those who are uncontrolled on existing treatments through medical note review.
  • Implement national guidance for acromegaly patients
  • Improve endocrine/pituitary services and pathways with the aim of improving the management of uncontrolled acromegaly patients
  • Provide an educational legacy to support improved management of acromegaly

 

Proposals for projects covering the following areas are out of scope of this call:

  • Projects bearing the name or class of specific medicines
  • Projects designed to increase the uptake of a single therapeutic agent or intervention (projects should be aimed at improving adherence to specific guidelines or patient pathways)
  • Applications for funding of services which should be provided as standard within the NHS
  • Interventional or observational clinical studies
  • In vitro or in vivo (animal) studies
  • Non-interventional studies, such as epidemiological studies
  • Outcomes research studies where the primary focus is to understand the results of particular healthcare practices and interventions as well as to monitor and improve the quality of care
  • Other types of independent research on disease states, including novel diagnostic screening tools and surveys

 

Pfizer processes these applications through the Pfizer Global Medical Grants System which enables the review and consideration of an individual grant request submissions from a healthcare organisation which is intended to support an independent medical and/or scientific initiative of that healthcare organisation intended for quality improvement and to improve patient outcomes, in an area of unmet medical need that is aligned with Pfizer’s medical and/or scientific strategies.

A Quality Improvement Grant is a type of grant that supports independent quality improvement projects for systematic and continuous actions, that lead to measurable improvements in healthcare services and the health status of individuals and targets patient groups, aimed to improve patient outcomes in areas of unmet medical need that do not relate to a Pfizer asset but that are aligned with Pfizer’s medical and/or scientific strategies (e.g., aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators, and quality assurance using methodologically rigorous protocols with an endpoint goal of readiness for application to practice.

For all independent grants, the grant requester and the healthcare organisation grantee is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the initiative.

Grants will be awarded on a first come first served basis subject to the criteria set out in the Call for IPCUA Grant Application, which also contains full details of the scope of this call.

 

Apply for Improving Patient Care in Uncontrolled Acromegaly (IPCUA)

Please include 'IPCUA' in the title of your application.

Note: First time users will need to use their Healthcare Organisation / NHS email address and Create a password.

If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the log in webpage

To contact Pfizer for any other purpose, including adverse event reports, medical information requests, or data protection enquiries please call 01304 616161

 

 

References

  1. American Association of Clinical Endocrinologist: 2011 Acromegaly Guideline Update

 

PP-RDP-GBR-0132 / March 2019